Phase II randomized clinical trial of Pazopanib alone and Pazopanib plus Gemcitabine in relapsed or metastatic soft tissue sarcoma.

Trial Profile

Phase II randomized clinical trial of Pazopanib alone and Pazopanib plus Gemcitabine in relapsed or metastatic soft tissue sarcoma.

Completed
Phase of Trial: Phase II

Latest Information Update: 30 Jun 2017

At a glance

  • Drugs Pazopanib (Primary) ; Gemcitabine
  • Indications Soft tissue sarcoma
  • Focus Therapeutic Use
  • Acronyms PAPAGEMO
  • Most Recent Events

    • 09 Jul 2016 Status changed from recruiting to completed.
    • 07 Jun 2016 Primary endpoint (Progression-free survival rate) has been met, according to a results presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
    • 07 Jun 2016 Results presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top